NanoVibronix, Inc today announced it has filed a new provisional patent application with the United States Patent and Trademark Office.
NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra Read More »
Ichnos Sciences Inc. today announced the company has been granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for its first-in-class biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47 for the treatment of relapsed/refractory multiple myeloma (MM).
Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced the appointment of Stephen Gorgol as chief financial officer.
Direct Biologics, LLC announced it has dosed the first patient in its Phase 1 clinical trial evaluating ExoFlo ™ for the treatment of patients with medically refractory Crohn’s disease.
Vivani Medical, Inc., an innovative, clinical-stage biopharmaceutical company that develops novel, long-term therapeutic implants, announced the filing of a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission for the proposed initial public offering of Cortigent, Inc.
En este Short os hablamos de un antiguo planeta que podría haber evitado que en la Tierra proliferara la vida. …
El planeta que podría haber acabado con la vida de la Tierra Read More »
Zura Bio Limited announced the closing of its business combination with JATT Acquisition Corp, a special purpose acquisition company, on March 20, 2023.
Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp Read More »
The 2023 Annual Meeting of American Academy of Dermatology Association was held from 17 to 21 March 2023 in New Orleans, Louisiana, United States.
Bergen, Norway, 21 March 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that Dr. Iman Barilero has joined the company as Chief Development Officer.
Cytovation appoints Iman Barilero as Chief Development Officer Read More »
Selecta Biosciences, Inc. and Sobi®, announced positive topline results from the Phase 3 DISSOLVE I & II placebo controlled randomized clinical trials to determine safety and efficacy of two different dose levels of SEL-212 in adult patients with chronic refractory gout.
